Keyphrases
Alternative Dosing Regimen
50%
Analytical Validation
50%
Antibody-drug Conjugate
50%
Antithrombotic Management
50%
Blood Samples
28%
Blood Sampling Methods
14%
Capillary Blood
21%
Capillary Blood Sample
50%
Chronic Ventilation
12%
Clinical Rules
14%
Clozapine
50%
Confidence Interval
14%
Dose Individualization
50%
Drug Groups
25%
Drug Recall
50%
Durvalumab
8%
Elective Admission
12%
Ethical Reasoning
8%
Finger Prick
21%
Hospital Pharmacy
50%
ICU Discharge
50%
Individualized Dosing
22%
Interactions between Genes
8%
Medication Alerts
50%
Medication Knowledge
50%
Medication Safety
9%
Medication Surveillance
14%
Medication Wastage
20%
Medication Waste
40%
Monoclonal Antibody
16%
Multiple Activities
10%
Neutropenic
9%
Nursing Facility
50%
Patient Experience
50%
Pharmaceutical Research
8%
Pharmacoeconomics
50%
Pharmacy Technician
14%
Potential Prescribing Omissions
16%
Potentially Inappropriate Medication
50%
Psychogeriatric Patients
25%
Ramucirumab
8%
STOPP
12%
Structured Medication Review
50%
Therapeutic Antibody
50%
Total Economic Value
10%
Trastuzumab Deruxtecan (T-DXd)
8%
Venipuncture
21%
Venous Blood
21%
Vitamin K Antagonists
12%
Ward Transfer
12%
Nursing and Health Professions
Antivitamin K
6%
Blood Sampling
50%
Capillary
50%
Clozapine
50%
Cohort Analysis
16%
Confidence Interval
14%
Deprescribing
50%
Electronic Health Record
16%
Health Care Quality
50%
Health Center
7%
Hospital Discharge
100%
Hospital Pharmacist
6%
Length of Stay
16%
Mental Health
7%
Outpatient
57%
Palliative Therapy
16%
Pharmacy Technician
25%
Psychogeriatric Nursing
50%
Retinol
6%
Sampling
14%
Teaching Hospital
16%
Therapeutic Drug Monitoring
7%
Treatment Outcome
50%
Vein Puncture
21%
Ward
16%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Drug Reaction
25%
Antibody Drug Conjugate
50%
Anticancer Drug
25%
Atezolizumab
25%
Case-Control Study
50%
Comorbidity
25%
Drug Development
8%
Durvalumab
25%
Hospital Pharmacy
50%
Ipilimumab
25%
Monoclonal Antibody
50%
Nivolumab
25%
Pembrolizumab
25%
Pharmacoeconomics
50%
Pharmacogenomics
50%
Pharmacotherapy
50%
Pharmacy Technician
14%
Prevalence
50%
Ramucirumab
25%
Trastuzumab Deruxtecan
25%
